Sugi Predict

Sugi Predict / Compounds / SCHEMBL4236573

SCHEMBL4236573

SCHEMBL4236573

CCCCN1CCC(N(C)c2ccc(C(=O)Nc3ccc(Oc4ccc(NC(=O)NC(CC)CC)cc4OC)cc3)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 9/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ MEN1 O00255 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PKM P14618 1/20 0.40
▸ MCHR2 Q969V1 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ USP2 O75604 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ HTR4 Q13639 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ TAS1R3 Q7RTX0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240513 0.94 MCHR1 (0.40) MCHR1SMN1; SMN2NPSR1MEN1MAPT
SCHEMBL4232419 0.90 TAS1R3 (0.39) MCHR1SMN1; SMN2NPSR1MAPTPKM
SCHEMBL4686765 0.89 MCHR1 (0.46) MCHR1SMN1; SMN2NPSR1MEN1GAA
SCHEMBL4236062 0.88 MCHR1 (0.47) MCHR1SMN1; SMN2NPSR1MEN1GAA
SCHEMBL4233894 0.88 MCHR1 (0.47) MCHR1SMN1; SMN2NPSR1MEN1GAA
SCHEMBL4236569 0.87 MCHR1 (0.46) MCHR1SMN1; SMN2NPSR1MEN1GAA
SCHEMBL4740848 0.86 MCHR1 (0.36) MCHR1SMN1; SMN2NPSR1MAPTMCHR2
SCHEMBL4228379 0.86 MCHR1 (0.41) MCHR1MEN1GAAMAPTKMT2A
SCHEMBL4236698 0.86 SMN1; SMN2 (0.46) MCHR1SMN1; SMN2NPSR1MEN1GAA
SCHEMBL4683906 0.85 KDR (0.36) MCHR1SMN1; SMN2NPSR1MCHR2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 — — EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 — — WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 — — EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MCHR1 47/4885SMN1; SMN2 1538/4885NPSR1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.